Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 165

1.

Cyclophilin A interacts with HIV-1 Vpr and is required for its functional expression.

Zander K, Sherman MP, Tessmer U, Bruns K, Wray V, Prechtel AT, Schubert E, Henklein P, Luban J, Neidleman J, Greene WC, Schubert U.

J Biol Chem. 2003 Oct 31;278(44):43202-13. Epub 2003 Jul 23.

2.

The intriguing cyclophilin A-HIV-1 Vpr interaction: prolyl cis/trans isomerisation catalysis and specific binding.

Solbak SM, Reksten TR, Wray V, Bruns K, Horvli O, Raae AJ, Henklein P, Henklein P, Röder R, Mitzner D, Schubert U, Fossen T.

BMC Struct Biol. 2010 Oct 4;10:31. doi: 10.1186/1472-6807-10-31.

3.

Structural characterization of the HIV-1 Vpr N terminus: evidence of cis/trans-proline isomerism.

Bruns K, Fossen T, Wray V, Henklein P, Tessmer U, Schubert U.

J Biol Chem. 2003 Oct 31;278(44):43188-201. Epub 2003 Jul 23.

4.

Induction of G2 arrest and binding to cyclophilin A are independent phenotypes of human immunodeficiency virus type 1 Vpr.

Ardon O, Zimmerman ES, Andersen JL, DeHart JL, Blackett J, Planelles V.

J Virol. 2006 Apr;80(8):3694-700.

5.

The host-pathogen interaction of human cyclophilin A and HIV-1 Vpr requires specific N-terminal and novel C-terminal domains.

Solbak SM, Wray V, Horvli O, Raae AJ, Flydal MI, Henklein P, Henklein P, Nimtz M, Schubert U, Fossen T.

BMC Struct Biol. 2011 Dec 20;11:49. doi: 10.1186/1472-6807-11-49.

7.

HIV-1 p6-Another viral interaction partner to the host cellular protein cyclophilin A.

Solbak SM, Reksten TR, Röder R, Wray V, Horvli O, Raae AJ, Henklein P, Henklein P, Fossen T.

Biochim Biophys Acta. 2012 Apr;1824(4):667-78. doi: 10.1016/j.bbapap.2012.02.002. Epub 2012 Feb 9.

PMID:
22342556
8.
9.
10.

Human immunodeficiency virus type 1 (HIV-1) Vpr functions as an immediate-early protein during HIV-1 infection.

Hrimech M, Yao XJ, Bachand F, Rougeau N, Cohen EA.

J Virol. 1999 May;73(5):4101-9.

11.
12.

Active site residues of cyclophilin A are crucial for its signaling activity via CD147.

Yurchenko V, Zybarth G, O'Connor M, Dai WW, Franchin G, Hao T, Guo H, Hung HC, Toole B, Gallay P, Sherry B, Bukrinsky M.

J Biol Chem. 2002 Jun 21;277(25):22959-65. Epub 2002 Apr 9.

13.

Altered HIV-1 Gag protein interactions with cyclophilin A (CypA) on the acquisition of H219Q and H219P substitutions in the CypA binding loop.

Gatanaga H, Das D, Suzuki Y, Yeh DD, Hussain KA, Ghosh AK, Mitsuya H.

J Biol Chem. 2006 Jan 13;281(2):1241-50. Epub 2005 Nov 7.

14.

Functional and structural characterization of synthetic HIV-1 Vpr that transduces cells, localizes to the nucleus, and induces G2 cell cycle arrest.

Henklein P, Bruns K, Sherman MP, Tessmer U, Licha K, Kopp J, de Noronha CM, Greene WC, Wray V, Schubert U.

J Biol Chem. 2000 Oct 13;275(41):32016-26.

15.
16.

Functional role of residues corresponding to helical domain II (amino acids 35 to 46) of human immunodeficiency virus type 1 Vpr.

Singh SP, Tomkowicz B, Lai D, Cartas M, Mahalingam S, Kalyanaraman VS, Murali R, Srinivasan A.

J Virol. 2000 Nov;74(22):10650-7.

17.

Characterization of a leucine-zipper-like domain in Vpr protein of human immunodeficiency virus type 1.

Wang L, Mukherjee S, Narayan O, Zhao LJ.

Gene. 1996 Oct 31;178(1-2):7-13.

PMID:
8921884
18.

Target cell cyclophilin A modulates human immunodeficiency virus type 1 infectivity.

Sokolskaja E, Sayah DM, Luban J.

J Virol. 2004 Dec;78(23):12800-8.

19.
20.

Biochemical mechanism of HIV-I Vpr function. Specific interaction with a cellular protein.

Zhao LJ, Mukherjee S, Narayan O.

J Biol Chem. 1994 Jun 3;269(22):15577-82.

Items per page

Supplemental Content

Write to the Help Desk